Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity

Shuting Shi; Haoru Zhu; Xinyu Xia; Zhihui Liang; Xuehu Ma; Bingbing Sun

doi:10.1016/j.vaccine.2019.04.055

journal article May 01, 2019

Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity

Shuting Shi Haoru Zhu

Vaccine Vol. 37 No. 24 pp. 3167-3178 · Elsevier BV

View at Publisher Save 10.1016/j.vaccine.2019.04.055

Topics

No keywords indexed for this article. Browse by subject →

References

131

[1]

<https://www.who.int/news-room/fact-sheets/detail/influenza-(seasonal)> [accessed 31 March, 2019].

[2]

<https://www.who.int/news-room/fact-sheets/detail/hepatitis-b> [accessed 31 March, 2019].

[3]

<https://www.who.int/en/news-room/fact-sheets/detail/poliomyelitis> [accessed 31 March, 2019].

[4]

Masson J-D, Thibaudon M, Bélec L, Crepeaux G. Calcium phosphate: a substitute for aluminum adjuvants; 2016. 10.1080/14760584.2017.1244484

[5]

Gupta "Aluminum compounds as vaccine adjuvants" Adv Drug Deliv Rev (1998) 10.1016/s0169-409x(98)00008-8

[6]

Glenny "Insoluble precipitates in diphtheria and tetanus immunization" Br Med J (1930) 10.1136/bmj.2.3632.244

[7]

Sun "Nanomaterial-based vaccine adjuvants" J Mater Chem B (2016) 10.1039/c6tb01131d

[8]

Hogenesch "Mechanism of immunopotentiation and safety of aluminum adjuvants" Front Immunol. (2012)

[9]

Sun "Engineering an effective immune adjuvant by designed control of shape and crystallinity of aluminum oxyhydroxide nanoparticles" ACS Nano (2013) 10.1021/nn404211j

[10]

Caulfield "Effect of alternative aluminum adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice" Human Vacc (2014) 10.4161/hv.3.4.4309

[11]

Al-Shakhshir "Effect of protein adsorption on the surface charge characteristics of aluminium-containing adjuvants" Vaccine (1994) 10.1016/0264-410x(94)90127-9

[12]

HogenEsch "Optimizing the utilization of aluminum adjuvants in vaccines: you might just get what you want" NPJ Vaccines (2018) 10.1038/s41541-018-0089-x

[13]

Novel cellular and molecular mechanisms of induction of immune responses by aluminum adjuvants

Vishukumar Aimanianda, Jean Haensler, Sebastien Lacroix-Desmazes et al.

Trends in Pharmacological Sciences 2009 10.1016/j.tips.2009.03.005

[14]

Li "Tailoring inorganic nanoadjuvants towards next-generation vaccines" Chem Soc Rev (2018) 10.1039/c8cs00028j

[15]

Awate "Mechanisms of action of adjuvants" Front Immunol (2013) 10.3389/fimmu.2013.00114

[16]

Gupta "In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid" Vaccine (1996) 10.1016/s0264-410x(96)00073-4

[17]

Hutchison "Antigen depot is not required for alum adjuvanticity" FASEB J (2012) 10.1096/fj.11-184556

[18]

Stability of aluminium-containing adjuvants during aging at room temperature

Lana S. Burrell, Joe L. White, Stanley L. Hem

Vaccine 2000 10.1016/s0264-410x(00)00031-1

[19]

Walls "Eosinophil response to alum adjuvants: involvement of t cells in non-antigen-dependent mechanisms" Proce Soc Experimental Biol Med (1977) 10.3181/00379727-156-39951

[20]

Hogenesch H. Mechanisms of stimulation of immune response by aluminium adjuvants; 2002. 10.1016/s0264-410x(02)00169-x

[21]

Mannhalter "Modulation of the human immune response by the non-toxic and non-pyrogenic adjuvant aluminium hydroxide: effect on antigen uptake and antigen presentation" Clin Exp Immunol (1985)

[22]

Ghimire "Alum increases antigen uptake, reduces antigen degradation and sustains antigen presentation by DCs in vitro" Immunol Lett (2012) 10.1016/j.imlet.2012.06.002

[23]

Sokolovska "Activation of dendritic cells and induction of CD4+ T cell differentiation by aluminum-containing adjuvants" Vaccine (2007) 10.1016/j.vaccine.2007.03.045

[24]

Sun "NLRP3 inflammasome activation induced by engineered nanomaterials" Small (2013) 10.1002/smll.201201962

[25]

Eisenbarth S, O'Connor W, Sutterwala F, Flavell R. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants; 2008. 10.1038/nature06939

[26]

Sun "Enhanced immune adjuvant activity of aluminum oxyhydroxide nanorods through cationic surface functionalization" ACS Appl Mater Interfaces (2017) 10.1021/acsami.7b05817

[27]

Franchi L, Nunez G. The Nlrp3 inflammasome is critical for aluminum hydroxide-mediated IL-1β secretion but dispensable for adjuvant activity; 2008. 10.1002/eji.200838549

[28]

Hem "Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation" Expert Rev Vacc (2007) 10.1586/14760584.6.5.685

[29]

Kaliński "T-cell priming by type-1and type-2 polarized dendritic cells: the concept of a third signal" Immunol Today (1999) 10.1016/s0167-5699(99)01547-9

[30]

Terhune "A role for impaired regulatory T cell function in adverse responses to aluminum adjuvant-containing vaccines in genetically susceptible individuals" Vaccine (2014) 10.1016/j.vaccine.2014.07.052

[31]

Flach "Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity" Nat Med (2011) 10.1038/nm.2306

[32]

Ramanathan V, Badenoch-Jones P, Turk JL. Complement activation by aluminum and zirconium compounds; 1979.

[33]

Egwang "The role of complement in the induction and regulation of immune responses" Immunology (1984)

[34]

Billiau "Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases" J Leukoc Biol (2001) 10.1189/jlb.70.6.849

[35]

O’Hagan D, Ott GS, Van Nest G, Rappuoli R, Del Giudice G. The history of MF59 (R) adjuvant: a phoenix that arose from the ashes; 2013.

[36]

Noel Masihi "Immunobiological activities of nontoxic lipid A: enhancement of nonspecific resistance in combination with trehalose dimycolate against viral infection and adjuvant effects" Int J Immunopharmacol (1986) 10.1016/0192-0561(86)90116-5

[37]

Kommareddy "Chapter 13 - MF59: a safe and potent adjuvant forhuman use" (2017)

[38]

Fang "The adjuvant MF59: A 10-Year perspective Gary Ott, Ramachandran Radhakrishnan" (2000)

[39]

Galli "H5N1 vaccine induces early CD4<sup>+</sup> T cell response that predicts long-term persistence of protective antibody levels" Proc Natl Acad Sci (2009) 10.1073/pnas.0813390106

[40]

Herbert "Antigenicity of soluble protein in the presence of high levels of antibody : a possible mode of action of the antigen adjuvants" Nature (1966) 10.1038/210747a0

[41]

Seubert "The adjuvants aluminum hydroxide and MF59 induce monocyte and granulocyte chemoattractants and enhance monocyte differentiation toward dendritic cells" J Immunol (2008) 10.4049/jimmunol.180.8.5402

[42]

O’Hagan "The mechanism of action of MF59 – an innately attractive adjuvant formulation" Vaccine (2012) 10.1016/j.vaccine.2011.09.061

[43]

Cioncada "Vaccine adjuvant MF59 promotes the intranodal differentiation of antigen-loaded and activated monocyte-derived dendritic cells" PLoS ONE (2017) 10.1371/journal.pone.0185843

[44]

Technology DD. Pandemrix-Adjuvanted H1N1 Inluenza Vaccine; 2017.

[45]

GlaxoSmithKline. Influenza A (H5N1) Virus Monovalent Vaccine, Adjuvanted; 2018.

[46]

Yam "AS03-adjuvanted, very-low-dose influenza vaccines induce distinctive immune responses compared to unadjuvanted high-dose vaccines in BALB/c Mice" Front Immunol (2015) 10.3389/fimmu.2015.00207

[47]

Wu "Particle-based platforms for malaria vaccines" Vaccine (2015) 10.1016/j.vaccine.2015.09.097

[48]

Garçon "Development and evaluation of AS03, an adjuvant System containing α-tocopherol and squalene in an oil-in-water emulsion" Expert Rev Vacc (2012) 10.1586/erv.11.192

[49]

Morel "Adjuvant System AS03 containing α-tocopherol modulates innate immune response and leads to improved adaptive immunity" Vaccine (2011) 10.1016/j.vaccine.2011.01.011

[50]

Moris "H5N1 influenza vaccine formulated with AS03A induces strong cross-reactive and polyfunctional CD4 T-cell responses" J Clin Immunol (2011) 10.1007/s10875-010-9490-6

Showing 50 of 131 references

Cited By

378

Recent Progress in the Vaccine Development Against Epstein–Barr Virus

Yin Dai, Botian Zhang · 2025

Viruses

Application prospect of polysaccharide in the development of vaccine adjuvants

Lei Feng, Jiarui Zhang · 2025

International Journal of Biological...

Recent Advances in Clinical Research of Prophylactic Vaccines Against Tuberculosis

Buyun Xu, Mengjuan Yuan · 2025

Vaccines

The Promise and Potential of Metal–Organic Frameworks and Covalent Organic Frameworks in Vaccine Nanotechnology

Yalini H. Wijesundara, Thomas S. Howlett · 2024

Chemical Reviews

Microparticulated Polygonatum sibiricum polysaccharide shows potent vaccine adjuvant effect

Kai Shen, Jinlong Zhang · 2024

International Journal of Pharmaceut...

Immunomodulatory Peptides as Vaccine Adjuvants and Antimicrobial Agents

Shiva Hemmati, Zahra Saeidikia · 2024

Pharmaceuticals

Liposomes, transfersomes and niosomes: production methods and their applications in the vaccinal field

Domenico Riccardi, Lucia Baldino · 2024

Journal of Translational Medicine

Impact of Immunosenescence on Vaccine Immune Responses and Countermeasures

Li Chen, Chengwei Shao · 2024

Vaccines

Vaccine adjuvants: mechanisms and platforms

Tingmei Zhao, Yulong Cai · 2023

Signal Transduction and Targeted Th...

An Overview of Vaccine Adjuvants: Current Evidence and Future Perspectives

Alessio Facciolà, Giuseppa Visalli · 2022

Vaccines

Intramuscular Inoculation of AS02-Adjuvanted Respiratory Syncytial Virus (RSV) F Subunit Vaccine Shows Better Efficiency and Safety Than Subcutaneous Inoculation in BALB/c Mice

Lijun Bian, Yu Zheng · 2022

Frontiers in Immunology

Use of Protamine in Nanopharmaceuticals—A Review

Ivana Ruseska, Katja Fresacher · 2021

Nanomaterials

Adjuvants for Coronavirus Vaccines

Zhihui Liang, Haoru Zhu · 2020

Frontiers in Immunology

Study of different routes of immunization using outer membrane vesicles of Neisseria meningitidis B and comparison of two adjuvants

Luciana T. Brito, Fabiana M. Rinaldi · 2020

Vaccine

Metrics

378

Citations

131

References

Details

Published: May 01, 2019
Vol/Issue: 37(24)
Pages: 3167-3178
License: View

Authors

Funding

National Natural Science Foundation of China Award: 31870919

Fundamental Research Funds for the Central Universities

Natural Science Foundation of Liaoning Province Award: 20180550597

Cite This Article

Shuting Shi, Haoru Zhu, Xinyu Xia, et al. (2019). Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity. Vaccine, 37(24), 3167-3178. https://doi.org/10.1016/j.vaccine.2019.04.055

Vaccine adjuvants: Understanding the structure and mechanism of adjuvanticity

You May Also Like